Wood John P M

Casson Robert J, Chidlow Glyn, Crowston Jonathan G, Williams Pete A, Wood John P M

Glaucoma involves impaired retinal ganglion cell energy metabolism; bioenergetic therapies show promise for neuroprotection and visual recovery in humans.

Ao Jack, Chidlow Glyn, Wood John P M, Casson Robert J

This study found that slit-lamp laser photobiomodulation is safe in rat retinas below 500 mW/cm², but higher doses can cause localized damage in pigmented eyes, guiding safe clinical application for retinal diseases.

Sia Paul Ikgan, Wood John P M, Chidlow Glyn, Casson Robert

Creatine protected retinal neurons in lab dishes, but despite elevated levels, it failed to protect retinal ganglion cells in live animal models of glaucoma, suggesting limited clinical benefit.

Casson Robert J, Chidlow Glyn, Wood John P M

Chidlow Glyn, Ebneter Andreas, Wood John P M, Casson Robert J

This study found lower microglial MHC II expression in rats correlated with less severe optic nerve damage in glaucoma, suggesting MHC II contributes to neurodegeneration.

Shibeeb O'Sam, Chidlow Glyn, Han Guoge, Wood John P M, Casson Robert J

Subconjunctival glucose protected rat retinal ganglion cells from ischemic damage and temporarily improved contrast sensitivity in human glaucoma, suggesting bioenergetic-based therapies warrant further investigation.

Sharma Shiwani, Burdon Kathryn P, Chidlow Glyn, Klebe Sonja, Crawford April, Dimasi David P et al.

This study found a genetic variant near TMCO1 linked to earlier glaucoma diagnosis and showed TMCO1 protein is present in eye tissues, suggesting its role in disease onset.

Casson Robert J, Chidlow Glyn, Wood John P M, Crowston Jonathan G, Goldberg Ivan

Glaucoma is a group of eye disorders defined by optic nerve damage, not solely high pressure. The abstract emphasizes experimental models should show this specific optic neuropathy for accurate study.

Casson Robert J, Chidlow Glyn, Ebneter Andreas, Wood John P M, Crowston Jonathan, Goldberg Ivan

This review defines neuroprotection terms for glaucoma, highlighting the need for clear definitions to translate new therapies from lab to clinic, as current IOP reduction isn't always sufficient.

Ebneter Andreas, Casson Robert J, Wood John P M, Chidlow Glyn

This study found experimental glaucoma causes persistent microglial activation throughout the visual pathway, correlating with axonal damage, even after IOP normalizes. This suggests microglia contribute to ongoing neurodegeneration.

Wood John P M, Chidlow Glyn, Tran Tuyet, Crowston Jonathan G, Casson Robert J

RGC-5 cells, widely used in glaucoma research, were found to express neuronal but not RGC-specific markers. TSA treatment best differentiated them into a neuronal phenotype, clarifying their utility as a neuronal, not RGC, model.

Chidlow Glyn, Holman Matthew C, Wood John P M, Casson Robert J

This rat study found chronic hypoperfusion causes rapid, proximal optic nerve infarction and subsequent degeneration, involving glial cell activation. This highlights the optic nerve's vulnerability to ischemia.

Van Bergen Nicole J, Wood John P M, Chidlow Glyn, Trounce Ian A, Casson Robert J, Ju Won-Kyu et al.

RGC-5 cells, widely used in glaucoma research, were recharacterized and found to be mouse, not rat, and lack true retinal ganglion cell markers, urging caution in their use as RGC models.

Chidlow Glyn, Wood John P M, Manavis Jim, Osborne Neville N, Casson Robert J

Studying OPN in injured rat retinas, researchers found OPN is normally in RGCs but dramatically increases in activated microglia after injury, suggesting its role in neuroinflammation and potential as a biomarker.

Casson Robert J, Chidlow Glyn, Wood John P M, Vidal-Sanz Manuel, Osborne Neville N

RGC injury (optic nerve transection/NMDA) protected photoreceptors from light-induced degeneration in rats. This suggests RGC health impacts photoreceptor vulnerability, potentially via glial activation and neurotrophic factors.

Osborne Neville N, Wood John P M, Cupido Alexander, Melena José, Chidlow Glyn

Topical flunarizine was studied for glaucoma. It significantly lowered IOP and protected retinal cells from ischemia and excitotoxicity by reducing calcium and sodium influx, suggesting a dual-action glaucoma treatment.